Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1515/jpem-2021-0067 http://scihub22266oqcxt.onion/10.1515/jpem-2021-0067 33818036!ä!33818036 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Pediatr+Endocrinol+Metab 2021 ; 34 (5): 539-545 Nephropedia Template TP {{tp|p=33818036|t=2021. Invisible burden of COVID-19: enzyme replacement therapy disruptions |pdf=|usr=}}{{33818036}} gab.com Text Invisible burden of COVID-19: enzyme replacement therapy disruptions JO: J Pediatr Endocrinol Metab http://www.kidney.de/pget.php?&tw=1&pmid=33818036 #FOAvip OBJECTIVES: Lysosomal storage diseases (LSD) constitute an important group of metabolic diseases, consisting of approximately 60 disorders. In some types of lysosomal diseases, enzyme replacement therapy (ERT) is administered intravenously in weekly or biweekly doses. Unfortunately, scheduled ERT during COVID-19 was disrupted. We considered the possibility of adverse outcomes caused by the disruption in the treatment of patients with lysosomal storage disorders. METHODS: During the COVID-19 pandemic, we conducted a questionnaire that was delivered via Internet to assess how this vulnerable patient group was affected by the pandemic in terms of their access to treatment and their disease-related symptoms. RESULTS: The questionnaire was filled out by 75 patients. There were 35 patients whose treatment dose was missed because of COVID-19. The most common reason for skipping treatment was not wanting to go to the hospital for fear of contracting COVID-19. These 35 patients missed a median of four doses of ERT (range: 1-16 dosages). Twenty-one patients (60%) claimed that they were affected physically by not taking ERT (20 mucopolysaccaridoses, 1 Fabry disease), whereas 14 (40%) did not. CONCLUSIONS: Interruption of ERT during the COVID-19 pandemic may have significant consequences. It may be beneficial to switch to home treatment or reserve dedicated facilities. With proper planning and management, the treatment disruptions of this particular group can be avoided. Twit Text FOAVip Invisible burden of COVID-19: enzyme replacement therapy disruptions ????J Pediatr Endocrinol Metab http://www.kidney.de/pget.php?&tw=1&pmid=33818036 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33818036 #FOAvip English Wikipedia <ref>{{Cite pmid|33818036}}</ref> Invisible burden of COVID-19: enzyme replacement therapy disruptions #MMPMID33818036 Kahraman AB; Yildiz Y; Ciki K; Akar HT; Erdal I; Dursun A; Tokatli A; Sivri HS J Pediatr Endocrinol Metab 2021[May]; 34 (5): 539-545 PMID33818036show ga OBJECTIVES: Lysosomal storage diseases (LSD) constitute an important group of metabolic diseases, consisting of approximately 60 disorders. In some types of lysosomal diseases, enzyme replacement therapy (ERT) is administered intravenously in weekly or biweekly doses. Unfortunately, scheduled ERT during COVID-19 was disrupted. We considered the possibility of adverse outcomes caused by the disruption in the treatment of patients with lysosomal storage disorders. METHODS: During the COVID-19 pandemic, we conducted a questionnaire that was delivered via Internet to assess how this vulnerable patient group was affected by the pandemic in terms of their access to treatment and their disease-related symptoms. RESULTS: The questionnaire was filled out by 75 patients. There were 35 patients whose treatment dose was missed because of COVID-19. The most common reason for skipping treatment was not wanting to go to the hospital for fear of contracting COVID-19. These 35 patients missed a median of four doses of ERT (range: 1-16 dosages). Twenty-one patients (60%) claimed that they were affected physically by not taking ERT (20 mucopolysaccaridoses, 1 Fabry disease), whereas 14 (40%) did not. CONCLUSIONS: Interruption of ERT during the COVID-19 pandemic may have significant consequences. It may be beneficial to switch to home treatment or reserve dedicated facilities. With proper planning and management, the treatment disruptions of this particular group can be avoided. |*Enzyme Replacement Therapy[MESH] |*SARS-CoV-2[MESH] |Adolescent[MESH] |Adult[MESH] |COVID-19/*epidemiology[MESH] |Child[MESH] |Child, Preschool[MESH] |Cost of Illness[MESH] |Cross-Sectional Studies[MESH] |Female[MESH] |Humans[MESH] |Lysosomal Storage Diseases/*drug therapy[MESH] |Male[MESH] |Middle Aged[MESH] |Surveys and Questionnaires[MESH]Invisible burden of COVID-19: enzyme replacement therapy disruptions (epmc).pdf DeepDyve Pubget Overpricing